[
    "NLDAEFC- \n\n Europium-amide). This substrate contained an N-terminal QSY7 moiety that served as a quencher of the C-terminal Europium fluorophore (620nm Em). In the absence of enzyme activity, 620 nm fluorescence was low in the assay and increased linearly over 3 hours in the presence of uninhibited BACE1 enzyme. Inhibition of BACE1 cleavage of the QSY7-APP<sup>swe</sup>-Eu substrate by inhibitors was manifested as a suppression of 620 nm fluorescence.</p>Varying concentrations of inhibitors at 3x the final desired concentration in a volume of 1OuI were preincubated with purified human BACE1 catalytic domain (3 nM in 10 Cl) for 30 minutes at 30\u00b0 C in reaction buffer containing 20 mM Na-Acetate pH 5.0, 10% glycerol, 0.1 % Brij-35 and 7.5% DSMO. Reactions were initiated by addition of 10 Cl of 600 nM QSY7-APP<sup>swe</sup>-Eu substrate (200 nM final) to give a final reaction volume of 30 Cl in a 384 well Nunc HTRF plate. The reactions were incubated at 30\u00b0 C for 1.5 hours. The 620nm fluorescence was then read on a Rubystar HTRF plate reader (BMG Labtechnologies) using a 50 Cs delay followed by a 400 millisecond acquisition time window. Inhibitor IC<sub>50</sub> values were derived from non-linear regression analysis of concentration response curves. K<sub>1</sub> values were then calculated from IC<sub>5O</sub> values using the Cheng-Prusoff equation using a previously determined Cm value of 8CM for the QSY7-APP<sup>swe</sup>-Eu substrate at BACE 1.</p>BACE inhibitor whole cell IC50 determination using HEK293-APP<sup>swe/lon</sup> cells</p>HEK293 cells were obtained from the American Type Culture Collection (ATCC) and stably transfected with the human amyloid precursor protein cDNA containing the FAD Swedish (enhances /?-secretase processing) and London (enhances A<sub>/</sub>542 cleavage) mutations. A HEK293 stable clone with A\u03b2 expression (HEK293-APP<sup>swe/lon</sup>) was identified and maintained at 37 <sup>0</sup>C, 5% CO<sub>2</sub> in the ATCC- recommended growth media supplemented with hygromycin. Determination of compound IC<sub>50</sub> values for inhibition of APP processing (reduction of A<sub>/</sub>51 -40, A/?1-42 and sAPP\u03b2 levels) in HEK293-APP<sup>swe/lo\u03c0</sup> cells was accomplished by treatment of cells with various concentrations of compounds diluted in fresh complete growth media for 4 hours at 37\u00b0C, 5% CO<sub>2</sub>. A\u03b240 or A/S42 were measured in 15 \u03bcl of media using a mesoscale based ELISA assay. Full length A/?40 and A/?42 peptides were captured \n\n with the N-terminal specific biotinylated-WO2 monoclonal antibody and detected using either the ruthenylated A/?40 C-terminal specific monoclonal antibody, G2-10 or the ruthenylated A/?42 C-terminal specific monoclonal antibody G2-11 respectively. Raw electrochemiluminescnce values were measured using a Mesoscale Sector Imager plate reader and were plotted as a function of compound concentration. IC<sub>50</sub> values were interpolated from the data using nonlinear regression ana",
    "o certain cytochrome p450 enzymes, and good selectivity with respect to hERG. In some embodiments, certain compounds or groups of compounds of the invention exhibit an unexpected combination of good potency for BACE-1 and one or more additional property such as: good selectivity with respect to Cathepsin D; good selectivity with respect to certain cytochrome p450 enzymes; good selectivity with respect to hERG; good pharmacokinetic profie; and/or good pharmacodynamic profile. Properties of example compounds of the invention may be appreciated, for example, by assaying for properties using known methods and/or by reference to Table IA below. (The example numbers in the left-most column of Table IA correspond to the example numbers for the compounds pictured in Table I, above.)</p>Table IA</p>CYP 2D6 CYP 3A4 CYP 2C9</p>IC<sub>5</sub>O uM IC<sub>5</sub>O uM IC<sub>50</sub> uM HERG lonworks HERG Rb efflux</p>BACE1 CathD %lnhi %lnh\u03b9 <sup>%l</sup>\"<sup>h</sup>' %lnh\u03b9b</p>-. . BAC E1 Example <sub>\u03ba| nM</sub> Ap<sub>4</sub>o ICM Select co pre pre pre b 10 b , <sup>D</sup><sub>n</sub>. 1.5 uG/ nM ivity uM 1 uM . mL mL</p>12 12 38 142 18 20</p>4 7 14 458 -30 26 6 &gt;30 &gt;30 &gt;30 &gt;30 45</p>15 8 5 28 158 13 5 -30 &gt;30 &gt;30 21 6 -30 57 \n\n Table IA</p>CYP 2D6 CYP 3A4 CYP 2C9</p>HERG lonworks HERG</p>IC<sub>50</sub> uM Ic<sub>50</sub> uM IC<sub>50</sub> uM Rb efflux</p>%lnhi</p>BACE1 CathD %lnhi %lnhi %lnhib</p>BACE1 b</p>Example CO pre pre CO CO pre b 10 b Kl nM Ap<sub>4</sub>O IC50 Select 1.5 uG/</p>O Uo/ nM ivity uM 1 uM mL</p>18 9.3 32 228</p>11 32 61 254</p>17 7.3 16 354 -30 25.5 24.1 &gt;30 &gt;30 &gt;30 74 10</p>4</p>59 323 248 -30 &gt;30 &gt;30 &gt;30 &gt;30 &gt;30 racemic</p>23 racemic 154 292 &gt;30 &gt;30 &gt;30 &gt;30 &gt;30 &gt;30</p>24 racemic 137 129 22.6 -30 &gt;30 &gt;30 &gt;30 &gt;30</p>5 racemic 61 217 -30 &gt;30 &gt;30 &gt;30 &gt;30 &gt;30</p>6 racemic 16 144 318 24.9 -30 &gt;30 &gt;30 &gt;30 &gt;30 \n\n Table IA</p>CYP 2D6 CYP 3A4 CYP 2C9</p>HERG lonworks HERG Rb efflux</p>IC<sub>50</sub> uM IC<sub>50</sub> uM IC<sub>50</sub> u M</p>%lnhi</p>BACE1 CathD %lnhi %lnhi %lnhib</p>BACE1</p>Example C<sub>50</sub> Select CO pre pre CO CO pre b 10 b Kl \u03c0M A\u03b2<sub>40</sub> I 3 UvJ/ 1.5 uG/ nM ivity uM 1 uM mL</p>7.7 35 446 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 89 21</p>25 44 racemic 349 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20</p>7 94 664 racemic</p>26</p>180 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 racemic</p>27 4.4 61.5 1063 14.7 -30 4.2 &gt;30 &gt;30 &gt;30 51</p>28 64 114 23.3 -30 &gt;30 &gt;30 &gt;30 &gt;30 14 13</p>5.6 66 386 &gt;30 &gt;30 18.6 &gt;30 -30 -30 71 12</p>10 7.5 583 -30 &gt;30 &gt;30 &gt;30 &gt;30 &gt;30 74 \n\n Table IA</p>CYP 2D6 CYP 3A4 CYP 2C9</p>HERG lonworks HERG Rb efflux</p>ICso uM IC<sub>50</sub> uM IC<sub>50</sub> uM</p>%lnhi</p>BACE1 CathD %lnhi %lnhi %lnhib</p>BACE1 D</p>Example A\u03b2<sub>40</sub> IC<sub>50</sub> Select CO pre pre CO CO pre b 10 b Kl nM 1.5 uG/ nM ivity uM 3 Uo/</p>1 uM mL</p>29 30 93 99 &gt;30",
    "ub>O Sele 1.5 uG/ nM ivity uM O UsJl</p>1 uM mL</p>37 26 235 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 73 12</p>38 27 31 209 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 63 12</p>19 68 117 236 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 20</p>42 11</p>41 32 67 346 77</p>16 60 165 143 &gt;30 &gt;30 &gt;30 &gt;30 &gt;30 &gt;30 61 11</p>14 43 213 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 59</p>39 racemic 92 40 221 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 61 \n\n Table IA</p>CYP 2D6 CYP 3A4 CYP 2C9</p>HERG lonworks HERG Rb efflux</p>IC<sub>50</sub> uM IC<sub>50</sub> uM IC<sub>50</sub> uM</p>%lnhi</p>BACE1 CathD %lnhi %lnhi %lnhib</p>BACE1</p>Example elect CO pre pre CO CO pre b 10 b 1.5 uG/ Kl nM A\u03b2<sub>4</sub>o IC<sub>50</sub> S nM ivity uM 1 uM mL</p>8.9 42 162 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 50</p>36 14 63 1202 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 37</p>40 53 224 151 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 81 15</p>13 109 230 &gt;20 &gt;20 &gt;20 &gt;20 S.5 12.7 89 22</p>44 6.1 25 352 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 67 14</p>45 7.3 23 341 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 72 17</p>43 16 21 116 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 &gt;20 27</p>20 4.5 9.5 106 &gt;20 &gt;20 3.3 &gt;20 7.5 8.9 93 29 \n\n Table IA</p>CYP 2D6 CYP 3A4 CYP 2C9</p>HERG lonworks HERG Rb efflux</p>IC<sub>50</sub> uM IC<sub>50</sub> uM IC<sub>50</sub> uM</p>BACE1 %lnhi</p>CathD %lnh\u03ca %lnhi</p>BACE1 %inhib</p>D</p>Example IC<sub>50</sub> Select CO pre pre CO CO pre b 10 b 1.5 uG/ KI nM A\u03b2<sub>4</sub>o O Uu/ nM ivity uM 1 uM mL</p>21 4.8 50 50 13.7 10.1 &gt;20 &gt;20 &gt;20 &gt;20 73</p>22 5.6 18 53 &gt;20 &gt;20 &gt;20 &gt;20 -20 &gt;20 96 35</p>While the present invention has been described with in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention. \n</p>"
]